VelociTx Inc.

VelociTx uses generative biology and AI-native acceleration to redesign CAR-T cell therapies from first principles.

We're the first to run generative protein design around a CAR's transmembrane domain, and discovered it can be a novel orchestration layer for creating better CAR-T cell therapies.